Sabestomig

DB19326InvestigationalProtein Based Therapies

Sabestomig is under investigation in clinical trial NCT05216835 (Safety and Preliminary Efficacy Assessment of AZD7789 in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma).

Mechanism: Pharmacologically active on Programmed cell death protein 1 and Hepatitis A virus cellular receptor 2
Curator reviewed
Also known as: Immunoglobulin G1 [239-phenylalanine,240-glutamic acid,336-serine,354-cysteine,371-serine,373-alanine,412-valine], bispecific, anti-(human programmed cell death protein 1) (human-Mus musculus clone LO115 γ1-chain) disulfide with human-Mus musculus clone · Immunoglobulin G1-kappa/lambda, anti-[Homo sapiens PDCD1 (programmed cell death 1, PD1, PD-1, CD279) and HAVCR2 (hepatitis A virus cellular receptor 2, T cell immunoglobulin and mucin domains family member 3, TIM3, TIM-3, TIMD3, CD366)], humanized and Ho
Code names: AZD7789

Resolves to

Compound

UNIIX79QP2R2CZCAS2648346-74-9

Targets

Q15116PDCD1Q8TDQ0HAVCR2

What you can answer from here — as of July 09, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

5Clinical trialsPhase, status and sponsor resolved per trial

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with Sabestomig, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account